Related Experiment Video
Updated: May 24, 2026
09:30
Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
Published on: March 17, 2023
Current and future state of FDA-CMS parallel reviews
1Center for Medical Technology Policy, World Trade Center-Baltimore, Baltimore, Maryland, USA. donna.messner@cmtpnet.org
Clinical Pharmacology and Therapeutics
|February 21, 2012
Summary
The US Food and Drug Administration (FDA) and Centers for Medicare and Medicaid Services (CMS) proposed parallel review for medical products. This aims to speed up market access and Medicare coverage, incentivizing developers to meet diverse stakeholder needs.
Area of Science:
- Health policy
- Medical product regulation
- Healthcare economics
Background:
- The US Food and Drug Administration (FDA) and Centers for Medicare and Medicaid Services (CMS) have historically operated separate review processes for new medical products.
- This separation can lead to delays in market availability and patient access to innovative therapies.
- Aligning review pathways is crucial for streamlining the medical product lifecycle.
Purpose of the Study:
- To introduce and explain the proposed "parallel review" process between the FDA and CMS.
- To highlight the potential benefits of this aligned review for medical product developers and patients.
- To discuss the implications for study design and data generation in medical product development.
Main Methods:
- The abstract describes a proposed policy change, not an empirical study.
- It outlines the concept of parallel review, where FDA and CMS review processes are partially aligned.
- The focus is on the potential impact and incentives created by this proposed alignment.
Main Results:
- The parallel review process may expedite market entry for certain medical products.
- It offers the potential for faster Medicare coverage decisions.
- New incentives may encourage product developers to generate data addressing the needs of regulators, payers, patients, and clinicians simultaneously.
Conclusions:
- The proposed parallel review represents a significant policy shift in medical product evaluation.
- This initiative has the potential to improve efficiency and coordination between regulatory and reimbursement bodies.
- It could foster the development of products that better meet the comprehensive needs of the healthcare ecosystem.
Related Concept Videos
01:26FDA Approved Drugs: Changes to Approved Drugs
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).